Barnes, David J.
Dutton, Peter
Bruland, Øyvind
Gelderblom, Hans
Faleti, Ade
Bühnemann, Claudia
van Maldegem, Annemiek
Johnson, Hannah
Poulton, Lisa
Love, Sharon
Tiemeier, Gesa
van Beelen, Els
Herbschleb, Karin
Haddon, Caroline
Billingham, Lucinda
Bradley, Kevin
Ferrari, Stefano
Palmerini, Emanuela
Picci, Piero
Dirksen, Uta
Strauss, Sandra J.
Hogendoorn, Pancras C. W.
Buddingh, Emmeline
Blay, Jean-Yves
Cleton-Jansen, Anne Marie
Hassan, Andrew Bassim
Article History
Received: 23 March 2022
Accepted: 19 May 2022
First Online: 8 June 2022
Declarations
:
: The MEMOS trial (NCT02441309 12/05/2015, ISRCTN46249783, EudraCT 2012–000615-84, EuroSarc-MEMOS) was a Phase II trial containing a randomised comparison sponsored by the University of Oxford and approved by UK national research ethics committee (14/SC/0255) and ratified by ethical review boards of the participant sites across Europe. The trial was co-ordinated by the Oxford Oncology Clinical Trials Office (OCTO). The trial was conducted under the sponsorship, European and national guidance for clinical trials, including patient confidentiality, safety, governance, reporting and regulatory reporting and conduct requirements.
: All authors and funders consent to publication of the manuscript. Participants who signed informed consent also consented for anonymised data communication through publications.
: ABH has received a second-class travel assistance grant and lecture honoraria from Takeda Pharma to a European orthopaedic conference. The Italian sarcoma group (members PP, SF, EP) have participated in another trial of MTP-PE in osteosarcoma. There are no other author conflicts, financial conflicts or non-financial competing interests in relation to this study.